China Allows Elicera's ELC-401 Glioblastoma Patent
China's patent office has issued a notice of allowance for a CAR T-cell therapy targeting glioblastoma, with protection running to 2041.
Updated on Nov. 5, 2026 in Biotech
The China National Intellectual Property Administration issued a notice of allowance for Elicera Therapeutics' patent application covering ELC-401, a CAR T-cell therapy for glioblastoma. The patent is expected to be formally granted shortly and would provide protection until 2041.
Why it matters
Glioblastoma is the most aggressive primary brain tumor, with a median survival of approximately 15 months despite standard treatments. Corresponding applications were previously allowed in the United States and granted in Japan, extending the patent's international footprint.
The notice is an allowance rather than a final grant, so formal issuance is still pending, with protection stated to run until 2041. Glioblastoma's approximately 15-month median survival under standard treatment provides the clinical baseline for the therapy's target population, though the source reports no trial results.
The players
Elicera Therapeutics
A Uppsala, Sweden-based biotechnology company developing cell and gene therapies, including the ELC-401 CAR T-cell candidate for glioblastoma.
China National Intellectual Property Administration
China's national patent office, responsible for examining and granting patents in the country.
The details
The patent application covers the component of ELC-401 that binds the protein IL-13Rα2, and the therapy is designed to target IL13Rα2-positive tumors. The iTANK platform, for which Elicera holds an earlier granted Chinese patent, is used to stimulate endogenous immune responses alongside the CAR T-cell approach.
Timeline
November 5, 2026: China's patent office announces the notice of allowance for ELC-401.
2041: Patent protection for ELC-401 is set to expire.
Roadmap
CAR T-cell therapies have transformed treatment for certain blood cancers, and extending the approach to solid tumors such as glioblastoma remains a central challenge in cell therapy research. This patent allowance positions Elicera's ELC-401 within that broader push to adapt the technology beyond hematologic malignancies.
For patients and families affected by glioblastoma, the allowance signals continued investment in new treatment approaches, though a patent does not by itself change access to therapy. Any clinical use would depend on further development and regulatory review, so the practical effect for patients remains distant.
The takeaway
Patent allowances mark a commercial and legal milestone rather than a clinical one, so readers should watch for trial data before expecting changes in glioblastoma care. The ELC-401 protection window extending to 2041 signals the long development horizon these therapies require.
Further reading
Explore more Biotech coverage for context on how cell therapy patents and clinical programs are developing.
Source note: This article includes information reported by Firstwordpharma.
